Form 4: Director Nelson Acquires Co-Diagnostics Stock

Director James B. Nelson acquired 1,695 shares of Co-Diagnostics, Inc. common stock on May 23, 2026, as part of a restricted stock unit award.

Summary

• Director James B. Nelson acquired 1,695 shares of Co-Diagnostics, Inc. common stock on May 23, 2026.
• The acquisition was made at a price of $0.00, indicating it was part of a restricted stock unit (RSU) award.
• Following this transaction, Mr. Nelson beneficially owns 10,668 shares of common stock directly.
• The acquired shares are part of RSUs awarded under the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan.
• These RSUs vest in six equal installments every six months, with vesting commencement dates varying based on the award date (November 23, 2023, November 23, 2024, and November 23, 2025).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It reports a standard insider transaction related to stock awards, which is a routine disclosure and does not provide new information on the company's financial health or strategic direction.

Positives

• Director acquisition of company stock can signal confidence in the company's future prospects.
• The acquisition is part of a long-term incentive plan, aligning management's interests with shareholders.
• The transaction involves restricted stock units, which are a common form of executive compensation designed to retain talent.

Negatives

• The acquisition was made at a $0.00 price, indicating it was an award rather than an open market purchase, which might not reflect a direct investment of personal capital.
• The filing does not provide details on the company's financial performance or strategic updates, focusing solely on a director's stock transaction.

Risks

• The vesting schedule of the restricted stock units means that the full benefit of the award is realized over an extended period, subject to continued employment.
• The value of the acquired shares is subject to the market performance of Co-Diagnostics, Inc. stock.

Future Outlook

The future outlook is not detailed in this filing, which exclusively reports a change in beneficial ownership. The vesting schedule of the restricted stock units implies a continued commitment from the reporting person over several years.

Management Comments

• The filing is a standard SEC Form 4 reporting a transaction by a director, and does not contain direct management comments or quotes.
• The signature indicates the transaction was reported by James Nelson, Director.

Industry Context

StockSavvy.ai notes that insider transactions, such as this Form 4 filing by a director, are routine disclosures. While they can sometimes signal confidence, this specific transaction involves awarded stock units rather than an open-market purchase, making its interpretation as a direct investment signal less pronounced.

Related Party Transactions

• The acquisition of 1,695 shares by Director James B. Nelson is a transaction involving a related party (a director of the company).

Stakeholder Impact

• Shareholders: The transaction itself does not immediately impact share price but reflects a component of executive compensation and director commitment.
• Employees: The long-term incentive plan, of which these RSUs are a part, is designed to motivate and retain key personnel.
• Management: The transaction is part of the compensation structure for the reporting person.

Next Steps

• Continued vesting of restricted stock units according to the specified schedule.
• Future Form 4 filings will be required for any further changes in beneficial ownership by Mr. Nelson.

Key Dates

Keywords

Form 4, SEC Filing, Co-Diagnostics, CODX, Insider Trading, Stock Acquisition, Restricted Stock Units, Director Compensation, Beneficial Ownership, Securities Exchange Act